Recent Company News

• 11:04 PM ET Jan 13, 2026
  

  Hutchmed notes Phase III SACHI results published in The Lancet (HK$23.70, +0.20)

• 10:11 PM ET Jan 06, 2026
  

  StreetAccount Summary - Trading higher/lower: Hong Kong mid-morning

• 07:06 PM ET Jan 06, 2026
  

  Hutchmed reports Phase III registration part of ESLIM-02 clinical trial of sovleplenib meets primary endpoint (HK$21.30, 0.00)

• 01:59 AM ET Jan 05, 2026
  

  StreetAccount Sector Summary - China Healthcare December Recap

• 07:13 PM ET Jan 04, 2026
  

  Hutchmed initiates Phase III stage of ongoing trial of surufatinib-camrelizumab combination to treat naïve pancreatic ductal adenocarcinoma (HK$20.94, 0.00)

• 05:34 AM ET Dec 30, 2025
  

  Hutchmed receives NMPA NDA acceptance with priority review status for savolitinib in met-amplified gastric cancer (HK$20.46, 0.00)

• 03:40 AM ET Dec 29, 2025
  

  Hutchmed receives NMPA NDA acceptance with priority review status for HMPL-453 in second-line intrahepatic cholangiocarcinoma (HK$20.54, 0.00)

• 07:03 PM ET Dec 16, 2025
  

  Hutchmed initiates global Phase I clinical development program for HMPL-A251 in patients with solid tumors (HK$20.30, 0.00)

• 08:33 PM ET Dec 07, 2025
  

  StreetAccount China Healthcare Sector Update: China reveals 2025 National Reimbursement Drug List, 114 newly added, 19 made commercial insurance list

• 07:15 PM ET Dec 07, 2025
  

  Hutchmed provides 2025 NRDL update; continue to include ELUNATE, ORPATHYS and SULANDA (HK$22.00, 0.00)